Lidocain/Prilocain Idetec and associated names

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
Opinion provided by Committee for Medicinal Products for Human Use


Update as of 12 November 2021:

The applicant for Lidocain/Prilocain Idetec and associated names has requested a re-examination of EMA’s October 2021 opinion. Upon receipt of the grounds of the request, the Agency will re-examine its opinion and issue a final recommendation.

On 14 October 2021, the European Medicines Agency completed a review of Lidocain/Prilocain Idetec and associated names following a disagreement among EU Member States regarding its authorisation. The Agency concluded that the benefits of Lidocain/Prilocain Idetec could not be shown to outweigh its risks, and the marketing authorisation cannot be granted in Denmark or in the other Member State of the EU where the company has applied for a marketing authorisation (in this case, the Netherlands).

Key facts

About this medicine
Approved name
Lidocain/Prilocain Idetec and associated names
International non-proprietary name (INN) or common name
  • lidocaine
  • prilocaine
Associated names
Lidocaïne / Prilocaïne 5% Focus, Crème
About this procedure
Current status
Opinion provided by Committee for Medicinal Products for Human Use
Reference number
Article 29(4) referrals

This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health.

Authorisation model
Nationally authorised product(s)
Decision making model
Key dates and outcomes
CHMP opinion date

All documents

Opinion provided by Committee for Medicinal Products for Human Use

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

  • Overview - lay-language summary of the stage of the procedure
  • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
  • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
  • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
  • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
  • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
  • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
  • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
  • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
  • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
  • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
  • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
  • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
  • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
  • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

Note that older documents may have different titles.


How useful was this page?

Add your rating
1 rating